Literature DB >> 2693303

Evaluation of serum laminin P1, procollagen-III peptides, and N-acetyl-beta-glucosaminidase for monitoring the activity of liver fibrosis.

M Schneider1, B Voss, B Högemann, G Eberhardt, U Gerlach.   

Abstract

Chronic liver diseases are characterized by an increase in connective tissue components in liver tissue. The determination of Col 1-3 peptide of type III procollagen (P-III-P) in serum of patients seems to be a useful parameter of hepatic fibroplasia. Specific radioimmunoassays are available for Col 1-3 (P-III-P) and the Col 1 and Col 1-3 (P-III-P-Fab) peptides of type III procollagen and for laminin P1 fragment. These proteins and the activity of N-acetyl-beta-glucosaminidase (beta-NAG) were measured in 94 patients with chronic liver diseases, and in 74 healthy controls. In addition, direct immunofluorescence studies were done for laminin P1 in normal and fibrotic liver tissues. In normal human liver, laminin was found in the basement membrane of bile ducts and in blood vessel walls. In fibrotic liver tissue, laminin additionally occurred in periportal areas and in sinusoids co-distributed with other connective tissue components. In serum concentrations of P-III-P, P-III-P-Fab and laminin were higher in patients than in healthy subjects. Laminin concentration was increased in early stages of chronic liver disease, possibly as a marker of regeneration; the highest concentrations were in active cirrhosis and chronic active hepatitis. The determination of P-III-P and P-III-P-Fab provided information on synthesis and degradation of type III collagen: In inactive cirrhosis, Col 1 peptide was increased in relation to Col 1-3 peptide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2693303

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Increased serum concentrations of type IV collagen and laminin associated with granulosa cell tumour of the ovary.

Authors:  M Iwahashi; M Ikoma; T Otani; A Ooshima; R Nakano
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

2.  Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine.

Authors:  Qunying Han; Sai Lou; Zhengwen Liu; Ni Zhang; Guoyu Zhang; Yi Lv; Shaoqiong Duan; Zhu Li
Journal:  Clin Exp Med       Date:  2010-02-05       Impact factor: 3.984

3.  Serum concentrations of laminin in cirrhosis of the liver.

Authors:  J Collazos; F Díaz; J Genollá
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

Review 4.  Is there a place for serum laminin determination in patients with liver disease and cancer?

Authors:  Heitor Rosa; Edison Roberto Parise
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.